Since 2006, intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs are being used to treat neovascular age-related macular degeneration (nAMD),[1] diabetic macular edema (DME),[2] retinal vein occlusion (RVO).[3] Repeated intravitreal anti-VEGF drugs are required to significantly improve the visual acuity and visual distortion and are widely concerned by ophthalmologists and patients. Here, VEGFA is linked to wet macular degeneration.